Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones

Abstract

The transgender community has expressed concerns regarding drug-drug interactions between HIV-pre-exposure prophylaxis (PrEP) and gender-affirming hormones. In this study, we evaluated emtricitabine (F, FTC)/tenofovir (TFV) disoporoxil fumarate (TDF) pharmacokinetics (PK) among adolescent and young adult transgender persons receiving gender-affirming hormone therapy (GAHT). This was a prospective, observational study among transgender women (TW) and men (TM) without HIV, 15–24 years of age, receiving GAHT (estradiol with/without spironolactone, or testosterone). Participants received 1 month of directly observed daily F/TDF. Weekly convenience blood samples were collected for plasma TFV and FTC, and intracellular TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP) in peripheral blood mononuclear cells (PBMC) and dried blood spots (DBS). After 2–3 weeks of F/TDF dosing, intensive PK sampling was conducted. PK parameters were estimated using noncompartmental methods. Data were log-transformed and compared between TM and TW, and to historical data among cisgender adults. Plasma TFV exposures were similar between TM and TW [geometric mean ratio (GMR); confidence interval (95% CI): 1.06 (0.89–1.28)], whereas FTC plasma exposures were 21% higher in TM versus TW (95% CI: 1.07–1.38). TFV-DP in PBMC and DBS and FTC-TP in DBS did not differ between TM versus TW after controlling for creatinine clearance (CrCl), but FTC-TP in PBMC remained 46% (95% CI: 1.15–1.86) higher in TM versus TW. All PK exposures were within expected ranges based on historical studies. TM had higher FTC exposures compared with TW, but overall plasma and intracellular exposures for both drugs were within the range of historical studies, suggesting high PrEP efficacy will be retained in adolescent and young adult transgender persons. Registered at ClinicalTrials.gov (NCT03652623)

Get full access to this article

View all access options for this article.

References

The Center for Disease Control and Prevention. HIV and Transgender Communities. [Issue Brief]. 2022. Available from: https://www.cdc.gov/hiv/pdf/policies/data/cdc-hiv-policy-issue-brief-transgender.pdf. [Last accessed: August 31, 2022].

Deutsch

, Glidden

, Sevelius

, et al. HIV pre-exposure prophylaxis in transgender women: A subgroup analysis of the iPrEx trial. Lancet HIV, 2015; 2(12):e512–e519; doi: 10.1016/S2352-3018(15)00206-4.

Mayer

, Molina

, Thompson

, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): Primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet, 2020; 396(10246):239–254; doi: 10.1016/S0140-6736(20)31065-5.

Cirrincione

, Podany

, Havens

, et al. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy. J Antimicrob Chemother, 2020; 75(5):1242–1249; doi: 10.1093/jac/dkaa016.

Cottrell

, Prince

HMA

, Schauer

, et al. Decreased tenofovir diphosphate concentrations in a transgender female cohort: Implications for human immunodeficiency virus preexposure prophylaxis. Clin Infect Dis, 2019; 69(12):2201–2204; doi: 10.1093/cid/ciz290.

Shieh

, Marzinke

, Fuchs

, et al. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. J Int AIDS Soc, 2019; 22(11):e25405; doi: 10.1002/jia2.25405.

Hiransuthikul

, Janamnuaysook

, Himmad

, et al. Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: The iFACT study. J Int AIDS Soc, 2019; 22(7):e25338; doi: 10.1002/jia2.25338.

Zheng

, Rower

, McAllister

, et al. Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal, 2016; 122:16–20; doi: 10.1016/j.jpba.2016.01.038.

Seifert

, Chen

, Meditz

, et al. Intracellular tenofovir and emtricitabine anabolites in genital, rectal, and blood compartments from first dose to steady state. AIDS Res Hum Retroviruses, 2016; 32(10–11):981–991; doi: 10.1089/AID.2016.0008.

10.

Schwartz

, Munoz

, Schneider

, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol, 2009; 20(3):629–637; doi: 10.1681/ASN.2008030287.

11.

Cockcroft

, Gault

. Prediction of creatinine clearance from serum creatinine. Nephron, 1976; 16(1):31–41; doi: 10.1159/000180580.

12.

Hendrix

, Andrade

, Bumpus

, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses, 2016; 32(1):32–43; doi: 10.1089/AID.2015.0182.

13.

Anderson

, Liu

, Castillo-Mancilla

, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother, 2018; 62(1); doi: 10.1128/AAC.01710-17.

14.

, Ai

, Zhang

, et al. Different effect of testosterone and oestrogen on urinary excretion of metformin via regulating OCTs and MATEs expression in the kidney of mice. J Cell Mol Med, 2016; 20(12):2309–2317; doi: 10.1111/jcmm.12922.

15.

Cirrincione

, Huang

. Sex and gender differences in clinical pharmacology: implications for transgender medicine. Clin Pharmacol Ther, 2021; 110(4):897–908; doi: 10.1002/cpt.2234.

16.

Shen

, Fahey

, Bodwell

, et al. Sex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture. PLoS One, 2014; 9(6):e100863; doi: 10.1371/journal.pone.0100863.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.08 MB

0.07 MB